

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

Assignment ID: PATI619131

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	OptMed, Inc.	12/08/2021
<b>RECEIVING PARTY DATA</b>		
<b>Company Name:</b>	H.B. Fuller Company	
<b>Street Address:</b>	1200 Willow Lake Blvd.	
<b>Internal Address:</b>	Box 64683	
<b>City:</b>	St. Paul	
<b>State/Country:</b>	MINNESOTA	
<b>Postal Code:</b>	55164-0683	
<b>PROPERTY NUMBERS Total: 4</b>		
	<b>Property Type</b>	<b>Number</b>
	Patent Number:	9487468
	Patent Number:	8794858
	Patent Number:	8829225
	Patent Number:	D651339
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	(781)718-9512	
<b>Email:</b>	welched@comcast.ent,welched123@gmail.com	
<b>Correspondent Name:</b>	Edward K Welch II	
<b>Address Line 1:</b>	IP&L Solutions	
<b>Address Line 2:</b>	2335 Tamiami Tr. N., Suite 307	
<b>Address Line 4:</b>	Naples, FLORIDA 34103	
<b>ATTORNEY DOCKET NUMBER:</b>	OptMed	
<b>NAME OF SUBMITTER:</b>	Edward Welch	
<b>SIGNATURE:</b>	Edward Welch	
<b>DATE SIGNED:</b>	11/08/2024	
<b>Total Attachments: 5</b>		

source=AssignmentOMtoHBfnl#page1.tiff  
source=AssignmentOMtoHBfnl#page2.tiff  
source=AssignmentOMtoHBfnl#page3.tiff  
source=AssignmentOMtoHBfnl#page4.tiff  
source=AssignmentOMtoHBfnl#page5.tiff

## ASSIGNMENT of PATENT RIGHTS

By virtue of a **Bill of Sale** executed December 8, 2021, **OptMed, Inc.**, a corporation of **Delaware**, having its principle office at **Suite 500, 745 Fifth Avenue, New York City, New York 10151, USA** transfers the entire right, title, and interest in and to the inventions and applications identified herewith, and in and to any division or continuation (in whole or in part) of the applications, and in and to any and all improvements in the inventions and in and to any and all Letters Patent, reexaminations, reissues, or extensions thereof of the United States of America and countries foreign thereto (including the right to apply for Letters Patent, Utility Models, or Inventors' Certificates in foreign countries in its own name and to claim any priority rights for such foreign applications to which such applications are entitled under international conventions, treaties, or otherwise), which have been or may be granted thereon or on any divisional, continuation (in whole or in part), renewal, reexamination, reissue, or other or further application based in whole or in part upon the invention or improvements thereon, any patents and pending patent applications identified herewith to **H.B. Fuller Company**, a corporation of Minnesota, having its principal office at **1200 Willow Lake Blvd., Box 64683, St. Paul, Minnesota 55164-0683, USA.**

And furthermore, by virtue of a Patent and Trademark Security Agreement Executed **July 11, 2016** and Recorded with the US Patent and Trademark Office on **July 12, 2016** (Reel/Frame 039131/073).

H.B. Fuller Company is the owner of the Patents and pending Patent Applications as further identified below, by said Bill of Sale which is enclosed herewith.

Therefore, **H.B. Fuller Company**, is desirous of the Recordation of Assignment to the entire right, title, and interest in and to the inventions and applications, and in and to any division or continuation (in whole or in part) of the applications, and in and to any and all improvements in the inventions and in and to any and all Letters Patent, reexaminations, reissues, or extensions thereof, of the United States of America and countries foreign thereto (including the right to apply for Letters Patent, Utility Models, or Inventors' Certificates in foreign countries in its own name and to claim any priority rights for such foreign applications to which such applications are entitled under international conventions, treaties, or otherwise), which have been or may be granted thereon or on any divisional, continuation (in whole or in part), renewal, reexamination, reissue, or other or further application based in whole or in part upon the invention or improvements thereon any patents and pending patent applications identified below;

U.S. Patent Appl No. **14/673,815**, filed **03/30/2015**, now Issued U.S. Pat. No. **9,487,468**,

U.S. Patent Appl No. **13/488,384**, filed **06/04/2012**, now Issued US. Pat. No. **8,794,858**,

U.S. Patent Appl No. **13/752,361**, filed **01/28/2013**, now Issued U.S. Pat. No. **8,829,225**, and

U.S. Patent Appl No. **29/356,172**, filed **02/20/2010**, now Issued U.S. Design Pat. No. **D651,339**.

## BILL OF SALE

THIS BILL OF SALE (this "Agreement") is entered into as of December, [ ], 2021, by and between OptMed, Inc., a Delaware corporation ("Company"), and H.B. Fuller Company, a Minnesota corporation, or its assignee ("Creditor"). Company and Creditor are each sometimes referred to as a "Party." In consideration of the matters in this Agreement and other good and valuable consideration, the receipt of which is hereby acknowledged, the Company hereby sells, conveys and transfers to the Creditor, by operation of Article 9 of the Uniform Commercial Code, as adopted in the State of New York (the "UCC"), all of the rights and interests of the Company in and to the property described on **Exhibit 1** attached hereto (the "Property") on an AS IS, WHERE IS basis, upon the following terms and conditions:

1. Delivery. The Creditor hereby accepts delivery of the Property. The Company shall have no further obligation to assemble or ship the Property.

2. Title; Limitation of Liability. The Creditor acknowledges that this is a disposition under the UCC. The Company warrants that it has good title, the right to sell and transfer the Property, that the Company has not heretofore sold, assigned, transferred or otherwise encumbered any or all of its right and interest in and to the Property, and that the Company has the right to transfer title to Creditor under the UCC. The Creditor holds a first priority perfected security interest in the Property under Article 9 of the UCC and no other person or entity has a lien or encumbrance which may be senior to the security interest of Creditor. The Company warrants that no stay, injunction, or order or decree of similar effect by any court or governmental entity having jurisdiction over the parties hereto is in effect prohibiting the Company from performing hereunder.

3. Exclusion of Certain Warranties. This sale is made on an AS IS, WHERE IS basis. Accordingly, except as set forth in Paragraph 2, THE COMPANY MAKES NO AFFIRMATIONS, PROMISES OR WARRANTIES, as to the Property or the condition, quality or operating characteristics of the Property, as to any prior use of the Property, or any other matter whatsoever, and the Creditor assumes all risks as to the quality and performance of the Property. THE COMPANY SPECIFICALLY DISCLAIMS AND EXCLUDES ANY WARRANTY OF MERCHANTABILITY AND ANY WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE.


4. Further Assurances. If the Creditor shall consider or be advised that any deeds, instruments of conveyance, assignments, assurances, or any other actions or things are necessary or desirable to vest, perfect, or confirm ownership (of record or otherwise) in the Creditor or the Creditor's right, title, or interest in, to, or under any or all of the Property transferred and conveyed by the Company hereunder, the Company shall execute and deliver all deeds, bills of sale, instruments of conveyance, powers of attorney, assignments, and assurances, and take and do all such other actions and things, in each case as may be reasonably requested by the Creditor in order to vest, perfect, or confirm any and all right, title, and interest in, to, and under such rights, properties, or assets in the Creditor.

5. Binding on Successors; No Third Party Beneficiaries. This Bill of Sale shall be binding upon and inure to the benefit of the parties hereto and the successors in interest and permitted assigns of such parties. This Bill of Sale is not intended to confer any rights or remedies upon any person other than the parties hereto.

6. Counterparts. This Bill of Sale may be executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. The delivery of copies of this Bill of Sale or other documents to be delivered pursuant to this Bill of Sale, including executed signature pages where required, by electronic transmission will constitute effective delivery of this Bill of Sale or such other document for all purposes.


Dated: December 8, 2021

COMPANY: OptMed, Inc.

By   
Its CEO

ACCEPTED AND AGREED TO BY  
CREDITOR:

H.B. Fuller Company

By   
Its Vice President & General Counsel

**EXHIBIT 1**  
**PROPERTY**

All right, title and interest of the Company in and to the following, in each case whether now owned or hereafter acquired or arising:

- (i) All Patents, including but not limited to the Specified Patents (listed below).
- (ii) All Trademarks, including not limited to the Specified Trademark (listed below).
- (iii) All accounts and other rights to payment (including but not limited to payments of royalties) arising from or relating to any Patent or Trademark.
- (iv) All rights to recover for all past, present, and future infringements, dilutions, preissuance recoveries and other violations of Patents and Trademarks.
- (v) All present and future license agreements with respect to the Patents and Trademarks.
- (vi) All proceeds of any and all of the foregoing.

**Specified Patents**

**Issued Patents**

OptMed Case No.	Country	Title	Patent No.	Issue Date
BRU-001	US	Method for Preparing Malonate Methylene Nanoparticles, Nanoparticles Optionally Containing One or Several Biologically Active Molecules	US 6,211,273 B1	4/3/2001
BRU-002	US	Poly(methylidene malonate) Microspheres, Preparation Method an Pharmaceutical Compositions Containing Them	US 6,440,461 B1	8/27/2002
BRU-003	US	Suture Material For Wounds Based on Methylidene Malonate	US 6,610,078 B1	8/26/2003
OM-001	US	Improved Methylidene Malonate Process	US 8,975,435 B2	3/10/2015
OM-002	US	Improved Methylidene Malonate Process	US 8,106,234 B2	1/31/2012
OM-003	US	Improved Methylidene Malonate Process	US 8,993,795 B2	3/31/2015
OM-004	US	Applicator	US D651,339S	12/27/2011
OM-005	US	Dispenser Handle	US 8,794,858 B2	8/5/2014
OM-007	US	1,1-Disubstituted Ethylene Process	US 8,829,225 B2	9/9/2014
P-75334-	US	COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING UROLITHIASIS	US 8,946,209 B2	2/03/2015

**Pending Patent Applications**

OptMed Case No.	Country	Title	Application No.	Filing Date
OM-001	EPO	Improved Methylidene Malonate Process	EP 10772397.5	5/6/2010
OM-001 CON1	US	“	USSN 14/642,730	3/09/2015
OM-003	EPO	Improved Methylidene Malonate Process	EP 10772395.9	5/6/2010
OM-003 CON1	US	“	USSN 14/673,815	3/30/2015
OM-006	US	Improved Applicator	USSN 13/488389	6/4/2012
OM-007	Brazil	Purification of 1,1-Disubstituted Ethylene	BR 11 2014 018497.6	1/28/2013
OM-007	China	“	CN2013800167357	1/28/2013
OM-007	EPO	“	EP 13706774.0	1/28/2013
OM-007	India	“	7106/DELNP/2014	1/28/2013
OM-008.1	Brazil	Improved Methylidene Malonate Process	BR 11 2014 0184950	1/28/2013
OM-008.1	China	“	CN2013800176746	1/28/2013
OM-008.1	EPO	“	EP 13704307.1	1/28/2013
OM-008.1	India	“	7162/DELNP/2014	1/28/2013
OM-008.1	US	“	USSN 14/628274	1/28/2013
OM-008.2	Brazil	Improved 1,1-Disubstituted Ethylene Process	BR 11 2014 018492.5	1/28/2013
OM-008.2	China	“	CN20138000175315	1/28/2013
OM-008.2	EPO	“	EP 13706775.7	1/28/2013
OM-008.2	India	“	7191/DELNP/2014	1/28/2013
OM-008.2	US	“	USSN 14/628273	1/28/2013

**Specified Trademark**

Mark	Country	Registration No.	Registration Date
BONDEASE	US	4,365,028	7/9/2013